TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00889356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 100mg and Ketoconazole 400mg
Description: 1 vaginal capsule once a day at night

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline 100mg and Amphotericin B 50mg
Description: One full applicator, once a day at night
Study: NCT04548310

Intervention type: OTHER
Intervention: Muscles Fatigue
Description: An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.

Intervention type: OTHER
Intervention: Muscles Fatigue
Description: An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
Study: NCT04691258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Complete Group
Description: The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Restricted Group
Description: The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base.
Study: NCT04112758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 2 times weekly for 5 weeks Circuit training with 4 stations
Study: NCT01242111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
Study: NCT01718717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Analgesia (TEA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA followed by Intravenous morphine
Study: NCT04475094

Intervention type: DRUG
Intervention: Rubidium-82
Description: Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.

Intervention type: BEHAVIORAL
Intervention: Seattle Angina Questionnaire-7
Description: Consented subjects will complete a SAQ-7.

Intervention type: BEHAVIORAL
Intervention: Rose Dyspnea Scale
Description: Consented subjects will complete a RDS.
Study: NCT04287153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy on abdomen and saddlebags
Description: Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
Study: NCT00928915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
Description: intravenous, repeated until INR ≤ 1.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
Description: intravenous, repeated until INR ≤ 1.2
Study: NCT04540198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GamePlan4Care
Description: GamePlan4Care; Experimental

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resources4Care
Description: R4C; Active Comparator
Study: NCT04822415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
Study: NCT03546959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lycra sleeve
Description: custom-fitted lycra sleeve extending from axilla to wrist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
Study: NCT02148029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Upper and Lower extremity exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: anticoagulation, compression, and ad-lib ambulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: anticoagulation, compression, and ad-lib ambulation
Study: NCT04168060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crura dissection
Description: The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crura dissection
Description: The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal hernia repair
Description: This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
Study: NCT04392154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study: NCT03546959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: Botulinum toxin injection for upper limb spasticity after stroke

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Botulinum toxin injection for upper limb spasticity after stroke
Study: NCT01217450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study: NCT00838279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fasting
Study: NCT03827356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainer (IMT)
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle trainer (IMT)
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
Study: NCT02283463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD) insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device (IUD) insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Study: NCT01217450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02211924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02175602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 milligrams administered each morning
Study: NCT02845349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
Study: NCT02175602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50 milligrams administered each morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: 75 milligrams single-agent film coated oral tablet administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: 75 milligrams single-agent film coated oral tablet administered twice daily
Study: NCT01718873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 IV every 2 weeks for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m2 IV every 2 weeks for up to 24 weeks
Study: NCT00231998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %
Study: NCT02845349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo comparator will be used in one subset of patients.
Study: NCT02590315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation for breast screening and random allocation
Description: Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation for breast screening and random allocation
Description: Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT
Description: Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional digital mammography.
Description: Conventional digital mammography.
Study: NCT04118972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror exposure and text prompt responses
Description: Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror exposure and text prompt responses
Description: Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
Study: NCT03132389

Intervention type: OTHER
Intervention: No intervention
Description: All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
Study: NCT02548182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smartcare
Description: Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smartcare
Description: Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: financial incentives
Description: Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
Study: NCT02106273

Intervention type: DEVICE
Intervention: Bronchial blocker (Coopdech, Arndt)
Description: Using bronchial blocker with LMA

Intervention type: DEVICE
Intervention: LMA-ProsealTM
Study: NCT03684057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-Delivered Mindfulness Training (MT)
Description: Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: App-Delivered Mindfulness Training (MT)
Description: Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
Study: NCT04027387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMB-365
Description: An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMB-365
Description: An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMB-365
Description: An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
Study: NCT01756001

Intervention type: DEVICE
Intervention: GlowCap
Description: The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
Study: NCT01718873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo-folinic acid
Description: 200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levo-folinic acid
Description: 200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
Study: NCT06629168

Intervention type: DIAGNOSTIC_TEST
Intervention: lumbar puncture
Description: Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.

Intervention type: DIAGNOSTIC_TEST
Intervention: lumbar puncture
Description: Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.

Intervention type: DIAGNOSTIC_TEST
Intervention: External lumbar drainage
Description: External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
Study: NCT01718873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
Study: NCT00082147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).